These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 2954863)

  • 1. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
    West CP; Lumsden MA; Lawson S; Williamson J; Baird DT
    Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
    Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
    Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The short-term use of luteinising hormone-releasing hormone analogues in uterine fibroids.
    Van der Spuy ZM; Fieggan AG; Wood MJ; Pienaar CA
    Horm Res; 1989; 32 Suppl 1():137-40. PubMed ID: 2533144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
    Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
    Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases.
    Lemay A
    Fertil Steril; 1987 Jul; 48(1):10-2. PubMed ID: 2954859
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of goserelin-depot in the clinical management of uterine fibroids.
    Cagnacci A; Paoletti AM; Soldani R; Angiolucci M; Arangino S; Falqui A; Melis GB
    Clin Exp Obstet Gynecol; 1994; 21(4):263-5. PubMed ID: 7994879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids.
    West CP; Lumsden MA; Hillier H; Sweeting V; Baird DT
    Hum Reprod; 1992 Mar; 7(3):328-32. PubMed ID: 1534089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri.
    Candiani GB; Vercellini P; Fedele L; Arcaini L; Bianchi S; Candiani M
    Acta Obstet Gynecol Scand; 1990; 69(5):413-5. PubMed ID: 2148663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding of steroids to myometrium and leiomyomata (fibroids) in women treated with the gonadotrophin-releasing hormone agonist Zoladex (ICI 118630).
    Lumsden MA; West CP; Hawkins RA; Bramley TA; Rumgay L; Baird DT
    J Endocrinol; 1989 May; 121(2):389-96. PubMed ID: 2526844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of LHRH analogue action in uterine fibroids.
    Shaw RW
    Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New possibilities for differentiated therapy of leiomyoma of the uterus using the GnRH agonist zoladex].
    Gesenhues T; Hackenberg R; Diechert U; Duda V; Sturm G; Schulz KD
    Geburtshilfe Frauenheilkd; 1989 Feb; 49 Suppl 1():96-8. PubMed ID: 2522904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
    Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
    Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
    Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
    J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
    McClelland HR; Quinn AJ
    Ulster Med J; 1992 Apr; 61(1):51-5. PubMed ID: 1535743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue.
    West CP; Baird DT
    Clin Endocrinol (Oxf); 1987 Feb; 26(2):213-20. PubMed ID: 2959405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
    Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
    Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
    Friedman AJ; Lobel SM; Rein MS; Barbieri RL
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women.
    Matta WH; Shaw RW; Burford GD
    Fertil Steril; 1988 Jan; 49(1):163-5. PubMed ID: 2961621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.